Abstract: In the past two decades, considerable progress has been made in the treatment of multiple myeloma (MM). The survival of MM patients has been significantly prolonged. However, most patients eventually relapse or become refractory to treatment. Thus, MM remains incurable. The expression of B cell maturation antigen (BCMA) is limited to some B cell lineages (both normal and malignant plasma cells) and is widely expressed on MM cells. Thus, BCMA is an ideal target antigen for MM. A variety of therapies targeting BCMA, including chimeric antigen receptor (CAR) T cells, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs), are currently in clinical trials in myeloma patients. Significant clinical responses have been achieved in patients with relapsed/refractory MM. This review summarizes the research progress of MM-targeted BCMA therapy in recent years.